All seven independent directors of 23andMe resigned from the board, citing disagreements with CEO Anne Wojcicki regarding the company’s strategic direction. Wojcicki expressed "disappointment" in the resignations but reaffirmed her commitment to taking the genetic-testing company private despite a rejected proposal in July. The special committee found no actionable proposal benefiting non-affiliated shareholders. 23andMe, which went public via a SPAC in 2021, has seen its share price drop over 95%, closing at 34 cents on Tuesday.
Category
🗞
NewsTranscript
00:00It's Benzinga, and here's what's on the block.
00:02All seven independent directors of 23andMe resigned from the board, citing disagreements
00:07with CEO Ann Wojcicki regarding the company's strategic direction.
00:11Wojcicki expressed disappointment in the resignations, but reaffirmed her commitment to taking the
00:15genetic testing company private despite a rejected proposal in July.
00:19The special committee found no actionable proposal benefiting non-affiliated shareholders.
00:2423andMe, which went public via a SPAC in 2021, has seen its share price drop over 95%,
00:30closing at $0.34 on Tuesday.
00:32For all things money, visit Benzinga.com.